Voting Results from the Combined Shareholders' General Meeting
Daix, France – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company dedicated to developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH), and other serious health conditions, has announced the results of its recent Combined Shareholders' Meeting.
Meeting Proceedings
The meeting, chaired by Mr. Frédéric Cren, Chairman and Chief Executive Officer and cofounder of Inventiva, included the usual formalities of meeting opening and the appointment of tellers and a secretary. All resolutions presented to the shareholders were adopted, except for the 59th resolution, which was advised against by the Board of Directors. This resolution proposed empowering the Board to decide on share capital increases for a savings plan.
Vote Results Summary
According to the approved documents, as mandated by Article R. 22-10-14 IV of the French Commercial Code, the shareholders reviewed and approved the compensation policy for corporate officers without any modifications as outlined in the Board of Directors' report.
Total Shares and Voting Rights
Details regarding the shareholders' votes are as follows:
- Total number of shares in share capital: 87,077,695
- Total number of shares with voting rights: 86,962,703
| Ordinary Resolutions | Vote Result | Votes For | % For | Votes Against | % Against |
|---|---|---|---|---|---|
| 1 | Adopted | 81,065,229 | 99.58% | 341,425 | 0.42% |
| 2 | Adopted | 81,066,149 | 99.58% | 340,505 | 0.42% |
| 3 | Adopted | 64,373,078 | 99.40% | 386,537 | 0.60% |
| 4 | Adopted | 81,021,688 | 99.53% | 383,921 | 0.47% |
| 59 | Rejected | 7,685,904 | 9.76% | 71,063,231 | 90.24% |
About Inventiva
Inventiva is pioneering biopharmaceutical research and innovation, focusing on oral therapies for MASH/NASH and other critical health issues. Capitalizing on their expertise in compounds designed to interact with nuclear receptors and transcription factors, Inventiva is advancing its lead candidate, lanifibranor, in pivotal Phase 3 trials.
Pipeline Insights
The company’s pipeline also features odiparcil, aimed at MPS VI treatment, although its development efforts regarding this product have been put on hold to prioritize lanifibranor. Inventiva also plans to identify new candidates for its Hippo signaling pathway program.
Contact Information
Inventiva operates with a dedicated team of approximately 90 professionals in various scientific disciplines, managing a vast collection of pharmacologically relevant compounds. For further inquiries, please reach out to:
Inventiva
Pascaline Clerc, PhD
EVP, Strategy and Corporate Affairs
media@inventivapharma.com
+1 202 499 8937
Brunswick Group
Tristan Roquet Montegon / Aude Lepreux / Julia Cailleteau
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83
Westwicke, an ICR Company
Patricia L. Bank
Investor relations
patti.bank@westwicke.com
+1 415 513-1284
Frequently Asked Questions
What were the key outcomes of the shareholder meeting?
The meeting resulted in the adoption of most resolutions except for the 59th resolution, which was rejected based on Board recommendations.
How many shares were represented at the meeting?
A total of 86,962,703 shares with voting rights were represented during the meeting.
What is Inventiva's main focus in recent research?
Inventiva is primarily focused on developing therapies for MASH/NASH, with its leading candidate being lanifibranor.
What plans does Inventiva have regarding its product pipeline?
Inventiva has plans to advance lanifibranor in clinical trials while exploring opportunities for additional candidates and reinstating the development of odiparcil in the future.
Where can I find more information about Inventiva?
For more details, you can visit www.inventivapharma.com.
